Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT03147768 Recruiting - Clinical trials for Pancreatic Neoplasms

Laser Tissue Welding - Distal Pancreatectomy Sealing Study

Start date: May 15, 2017
Phase: Phase 1
Study type: Interventional

The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure. The hypothesis is that the laser tissue welding device is safe and effective in sealing the pancreas, thereby decreasing the blood loss (operative and post-operative), and pancreatic juice leakage for patients when the Laser Tissue Welding device is used after pancreatic resection.

NCT ID: NCT03145857 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Start date: July 2017
Phase: Phase 1/Phase 2
Study type: Interventional

A [68]Ga-HA-DOTATATE PET/CT scan is a nuclear medicine test used to create pictures of the whole body that will show where somatostatin receptors are found, including on tumours. Somatostatin receptors are found on most neuroendocrine tumours (NETs), and some other types of tumours. Currently at the Cross Cancer Institute, most patients with suspected somatostatin positive tumours (e.g. NETs) have an Octreoscan™. A scientific study has shown that a scan with a similar product ([68]Ga-DOTATATE) is more accurate than an Octreoscan™. This study will look at [68]Ga-HA-DOTATATE scans, a product virtually identical to [68]Ga-DOTATATE. The purpose of this study is to: 1) demonstrate the safety of [68]Ga-HA-DOTATATE; and 2) confirm that [68]Ga-HA-DOTATATE is effective at diagnosing somatostatin positive tumours.

NCT ID: NCT03143946 Recruiting - Clinical trials for Neuroendocrine Tumor

DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor

Start date: December 2016
Phase: N/A
Study type: Interventional

This study aims to investigate if the proportion of neuroendocrine tumor (NET) patients with normal vitamin values can be increased, with vitamin suppletion and a personalized diet, Effects of the intervention will be evaluated by quantitative analysis of blood and urine and questionnaires. The measurements, will be performed at baseline (t=0), after 4 weeks (t=4) and after 18 weeks at end of study (t=18). Furthermore at t=18 a semi-qualitative interview will be performed.

NCT ID: NCT03136328 Completed - Clinical trials for Neuroendocrine Tumors

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET-CT Scan

Start date: May 16, 2016
Phase: Phase 3
Study type: Interventional

About 40 patients with histologically and/or clinically confirmed and/or suspected NET are anticipated to be enrolled during 3 years from initiating the study. Patients will be recruited at Montefiore Medical Park where there is a medical group specialized in the diagnosis and treatment of NETs. Each patient will undergo a screening visit within 14 days prior to receiving study medication. The primary goal of the analysis is to estimate the diagnostic accuracy of 68Ga-DOTATOC PETCT for detecting NET compared to conventional imaging techniques.

NCT ID: NCT03130205 Recruiting - Clinical trials for Neuroendocrine Tumors

Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours

Start date: May 1, 2017
Phase: N/A
Study type: Observational

The biology of pancreatic neuroendocrine tumors can change during the disease course. This evolution of disease can manifest through increases in tumor proliferation rate, resistance to medical therapy and/or a change in tumor hormone secretion. This study aims to characterize how the biology of pancreatic neuroendocrine tumors change over time, measured by; patient symptoms, biochemistry, contrast enhanced computed tomography, FDG-PET and core needle biopsy with histopathological analysis (Ki67 index and tumor cell differentiation). Uptake on 18F-FDG-PET will be correlated directly to tumor cell proliferation rate. Fraction of patients with spatial heterogeneity in FDG uptake as well as metachronous changes in all collected data will be documented. Biomaterial from whole blood and core needle biopsies will be characterized on the molecular level, and those findings will be integrated to the above specified clinical parameters.

NCT ID: NCT03112694 Recruiting - Clinical trials for Neuroendocrine Tumors

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Start date: April 4, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.

NCT ID: NCT03095274 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin

Start date: March 2017
Phase: Phase 2
Study type: Interventional

Well-differentiated gastroenteropancreatic and lung neuroendocrine tumors are generally malignancies with a prolonged natural history. However, clinical behavior is heterogeneous and when tumor progression is observed, treatment options are limited. The most used therapy for neuroendocrine tumors management are somatostatin analogs. However, even the use in lung carcinoids is quite usual, no antitumoral activity has been demonstrated. Tremelimumab and Durvalumab combination could be more efficient drugs to improve immune system activation and could obtain a significantly higher clinical benefit in these patients. Tremelimumab and Durvalumab would be the first immune combination agents showing efficacy in neuroendocrine neoplasms of different origins.

NCT ID: NCT03083210 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Start date: December 1, 2016
Phase: Phase 4
Study type: Interventional

Clinical data from uncontrolled retrospective or prospective studies have initially demonstrated antiproliferative effects of lanreotide in limited number of patients lanreotide Autogel® has recently been approved in more than 40 countries for the treatment of GEP-NET patients, this is based on the results of CLARINET study, the largest prospective trial to evaluate the antiproliferative effects of lanreotide Autogel® in subjects with nonfunctional GEP-NETs. The study enrolled 204 subjects (101 subjects were randomized to lanreotide Autogel® group and 103 subjects were randomized to placebo group, came from 14 countries) with well or moderately differentiated non-functioning GEP-NETs, including pancreatic and gastrointestinal tumors, and defined as having less than 10% of proliferation marker Ki67. The study had shown that treatment with lanreotide Autogel® significantly prolonged progression-free survival in subjects with GEP-NETs compared to treatment with placebo in the primary analysis (median progression-free survival, not reached vs. 18.0 months, P< 0.001 by the stratified log-rank test; hazard ratio for progression or death with lanreotide vs. placebo, 0.47; 95% confidence interval (CI), 0.30 to 0.73) [5]. The indication of GEP-NETs granted for lanreotide Autogel® in the USA is for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and in the European Union (EU) is for treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumors of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease. The addition of an indication for the treatment of patients with GEP-NETs has been approved by more than 15 other authorities including in Canada, Australia and some Asian countries, etc.

NCT ID: NCT03079440 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Start date: May 2017
Phase: Phase 2
Study type: Interventional

GI tract including pancreas is the one of most common primary sites of neuroendocrine tumors. Current grading of neuroendocrine tumors are based on the 2010 WHO classification. This classifies grade 3 tumors as the neuroendocrine tumor with mitosis > 20 per 10 high power field or Ki-67 labeling index > 20%. Etoposide-based chemotherapy, mostly as the combination with cisplatin, has been the mainstay of the treatment for patients with grade 3 neuroendocrine tumors. However, a recent large retrospective analysis has suggested this regimen may not be effective in relatively low Ki-67 labeling index. Therefore, the investigators designed a clinical trial testing temozolomide-capecitabine combination, which has been mostly investigated in well differentiated (ie., grade 1 or 2) neuroendocrine tumors, in patients with grade 3 and low Ki-67 gastroenteropancreatic neuroendocrine tumors.

NCT ID: NCT03070301 Recruiting - Clinical trials for Neuroendocrine Tumors

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Start date: February 27, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.